NEURO-ONCOLOGY ADVANCES

Edit Your Profile

NEURO-ONCOLOGY ADVANCES Journal

publication venue for

Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease. 6. 2024
Temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade gliomas. 5. 2023
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. 5.
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. 2.
Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis
Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance

Electronic International Standard Serial Number (EISSN)

2632-2498